Show simple item record

AuthorAlhmoud, Eman Nawash
AuthorElewa, Hazem
AuthorAbdul Gelil, Mohammed S.
AuthorAbd El Samad, Osama B.
AuthorElzouki, Abdelnasser Y.
Available date2023-09-20T08:47:11Z
Publication Date2020
Publication NameClinical and Applied Thrombosis/Hemostasis
ResourceScopus
ISSN10760296
URIhttp://dx.doi.org/10.1177/1076029620945039
URIhttp://hdl.handle.net/10576/47803
AbstractLow SAMe-TT2R2 score of <2 was validated as a predictor of optimum anticoagulation control, reflected by mean time in therapeutic range (TTR) above 65% to 70%, among warfarin-treated atrial fibrillation patients. This study aimed to validate the ability of SAMe-TT2R2 score and its individual components in predicting anticoagulation control (mean TTR and clinical events) among a cohort of venous thromboembolism (VTE) patients in Qatar. A total of 295 patients were retrospectively evaluated. There was a trend toward statistical significance in mean TTR between low (<2) and high (≥ 2) SAMe-TT2R2 score groups (P = .05), a difference that was not sustained when a cutoff of 3 was used (ie, a score of 3 or more). Patients with poor INR control (TTR <70%) were numerically less likely to have SAMe-TT2R2 score of <2 compared with those with good INR control, though the difference was not statistically significant (16.7% vs 83.3%, respectively, P = .4). No thromboembolic events were reported, and no association was found between the score and risk of bleeding. Non-Caucasian origin was the only significant predictor of good anticoagulation in the studied cohort. In conclusion, SAMe-TT2R2 score could not predict quality of anticoagulation control in a cohort of VTE patients treated with warfarin in Qatar. Contribution of other clinical factors and whether a different scoring may yield better prediction of anticoagulation control remains to be tested.
SponsorThe authors disclose receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Medical Research Center in Hamad Medical Corporation. The authors would like to thank Mr Walid Mekkawi and Dr Sayed Yameen, senior pharmacists, for their contribution in data collection. The authors disclose receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Medical Research Center in Hamad Medical Corporation.
Languageen
PublisherSAGE Publications Inc.
Subjectanticoagulation control
SAMe-TT2R2 score
time in therapeutic range
venous thromboembolism
TitleEvaluation of the Validity of SAMe-TT2R2 Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin
TypeArticle
Volume Number26
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record